- Home
- GLPG vs INOD Comparison
GLPG vs INOD Comparison
Compare GLPG & INOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- INOD
- Stock Information
- Founded
- GLPG 1999
- INOD 1988
- Country
- GLPG Belgium
- INOD United States
- Employees
- GLPG N/A
- INOD N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- INOD EDP Services
- Sector
- GLPG Health Care
- INOD Technology
- Exchange
- GLPG Nasdaq
- INOD Nasdaq
- Market Cap
- GLPG 2.1B
- INOD 1.6B
- IPO Year
- GLPG 2005
- INOD 1993
- Fundamental
- Price
- GLPG $32.26
- INOD $66.95
- Analyst Decision
- GLPG Sell
- INOD Strong Buy
- Analyst Count
- GLPG 4
- INOD 4
- Target Price
- GLPG $25.33
- INOD $57.50
- AVG Volume (30 Days)
- GLPG 168.5K
- INOD 2.6M
- Earning Date
- GLPG 10-29-2025
- INOD 11-06-2025
- Dividend Yield
- GLPG N/A
- INOD N/A
- EPS Growth
- GLPG N/A
- INOD 1136.64
- EPS
- GLPG N/A
- INOD 1.28
- Revenue
- GLPG $323,674,692.00
- INOD $228,141,000.00
- Revenue This Year
- GLPG N/A
- INOD $48.07
- Revenue Next Year
- GLPG N/A
- INOD $21.56
- P/E Ratio
- GLPG N/A
- INOD $52.23
- Revenue Growth
- GLPG 5.43
- INOD 112.54
- 52 Week Low
- GLPG $22.36
- INOD $13.02
- 52 Week High
- GLPG $33.86
- INOD $71.00
- Technical
- Relative Strength Index (RSI)
- GLPG 51.29
- INOD 82.06
- Support Level
- GLPG $31.49
- INOD $60.70
- Resistance Level
- GLPG $33.63
- INOD $66.37
- Average True Range (ATR)
- GLPG 0.66
- INOD 3.85
- MACD
- GLPG -0.06
- INOD 2.96
- Stochastic Oscillator
- GLPG 50.18
- INOD 93.23
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About INOD Innodata Inc.
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.